391 Wallace Rd, Nashville, TN, 37211 · (615) 781-4000
Beds
112
FY 2025
Star rating
4 of 5
Patient survey: 3 of 5
Net patient revenue
$163.6M
FY 2025
Net income
$29.0M
Patient care margin 17.0%
Discharges
5,005
Occupancy 51.7%
Clinicians
205
From the hospital's yearly cost reports (fiscal years as the hospital reports them)
Locations are shown at the center of the ZIP code.
US dollars as reported. Patient care margin = net patient revenue minus operating expenses, before other income such as grants, donations and investments.
| Fiscal year | Net patient revenue | Operating expenses | Patient care margin | Net income | Discharges | Uncompensated care | Medicare days | Medicaid days |
|---|---|---|---|---|---|---|---|---|
| 2025 | $163.6M | $135.7M | 17.0% | $29.0M | 5,005 | $21.8M | 17.1% | 8.3% |
Official hospital quality measures with the national median across hospitals. For ratios, 1.00 means as many cases as expected.
| Death rate for COPD patients | 8.3% | US median 8.5% |
| Death rate for heart attack patients | 11.2% | US median 11.8% |
| Death rate for heart failure patients | 14.7% | US median 11% |
| Hospital-wide death rate within 30 days | 3.9% | US median 3.9% |
| Death rate for pneumonia patients | 15.5% | US median 15.2% |
| Death rate for stroke patients | 10.5% | US median 11.6% |
Medicare clinicians who list this hospital, by specialty
Inpatient stays by diagnosis related group (DRG), 2024
Official US government data: hospital records, ownership records, yearly cost reports and quality measures, linked by the hospital's CCN and NPI. Financials are for fiscal years as reported by the hospital.
Medicare clinicians who work here
| 2024 | $154.7M | $128.3M | 17.0% | $27.7M | 5,144 | $19.8M | 15.5% | 16.1% |
| 2023 | $145.2M | $121.5M | 16.4% | $24.8M | 5,242 | $20.2M | 18.2% | 18.5% |
| 2022 | $138.4M | $119.1M | 14.0% | $19.6M | 5,228 | $17.7M | 19.4% | 16.4% |
| 2021 | $142.3M | $108.8M | 23.5% | $28.6M | 5,129 | $15.9M | 22.3% | 13.8% |
| 2020 | $114.5M | $95.3M | 16.8% | $22.3M | 4,570 | $14.9M | 26.3% | 15.7% |
| Readmission rate for COPD | 19.2% | US median 19.8% |
| Readmission rate after a heart attack | 14.1% | US median 14.4% |
| Readmission rate for heart failure | 22.3% | US median 21.3% |
| Readmission rate for pneumonia | 17.4% | US median 17.2% |
| Serious complications (patient safety composite) | 0.93 | US median 0.96 |
| C. diff intestinal infections (ratio to expected) | 0.21 | US median 0.28 · better |
| Central line bloodstream infections (ratio to expected) | 0.00 | US median 0.48 |
| Surgical site infections after colon surgery (ratio to expected) | 1.78 | US median 0.72 |
| MRSA bloodstream infections (ratio to expected) | 0.72 | US median 0.60 |
| Catheter urinary tract infections (ratio to expected) | 0.35 | US median 0.40 |
| Doctors always communicated well | 77% | US median 79% |
| Nurses always communicated well | 77% | US median 80% |
| Patient survey summary star rating | 3 of 5 | US median 3 of 5 |
| Area around the room always quiet at night | 62% | US median 59% |
| Patients who rated the hospital 9 or 10 out of 10 | 72% | US median 72% |
| Room and bathroom always clean | 74% | US median 73% |
| Patients who would definitely recommend the hospital | 64% | US median 71% |
| Patients who left the emergency department before being seen | 0% | US median 1% |
| Median time in the emergency department before leaving (minutes) | 119 min | US median 148 min |
| Patients prescribed 2 or more opioids or opioids with benzodiazepines at discharge | 17% | US median 15% |
| Patients who got appropriate care for severe sepsis and septic shock | 74% | US median 65% |
| Healthcare workers given the flu vaccine | 38% | US median 79% |
| Stroke patients who got a brain scan within 45 minutes of arrival | 62% | US median 74% |
| 26 |
| $59,344.35 |
| $9,744.69 |
| $9,867.73 |
| DRG 853 INFECTIOUS AND PARASITIC DISEASES WITH O.R. PROCEDURES WITH MCC | 24 | $212,745.83 | $32,963.21 | $40,556.82 |
| DRG 640 MISCELLANEOUS DISORDERS OF NUTRITION, METABOLISM, FLUIDS AND ELECTROLYTES WITH MCC | 22 | $62,228.14 | $9,416.23 | $10,642.23 |
| DRG 189 PULMONARY EDEMA AND RESPIRATORY FAILURE | 20 | $51,871.20 | $9,366.30 | $9,973.97 |
| DRG 682 RENAL FAILURE WITH MCC | 17 | $56,676.88 | $10,367.94 | $11,457.18 |
| DRG 177 RESPIRATORY INFECTIONS AND INFLAMMATIONS WITH MCC | 16 | $51,553.81 | $11,935.63 | $12,667.88 |
| DRG 872 SEPTICEMIA OR SEVERE SEPSIS WITHOUT MV >96 HOURS WITHOUT MCC | 16 | $54,164.63 | $6,769.19 | $7,681.44 |
| DRG 683 RENAL FAILURE WITH CC | 16 | $47,680.25 | $6,814.56 | $6,629.69 |
| DRG 280 ACUTE MYOCARDIAL INFARCTION, DISCHARGED ALIVE WITH MCC | 15 | $57,975.07 | $12,205.13 | $12,400.10 |
| DRG 454 COMBINED ANTERIOR AND POSTERIOR SPINAL FUSION WITH CC | 14 | $434,995.57 | $46,207.71 | $49,528.71 |
| DRG 208 RESPIRATORY SYSTEM DIAGNOSIS WITH VENTILATOR SUPPORT <=96 HOURS | 13 | $130,125.00 | $14,889.46 | $21,993.66 |
| DRG 481 HIP AND FEMUR PROCEDURES EXCEPT MAJOR JOINT WITH CC | 11 | $115,549.09 | $15,589.00 | $15,801.33 |
Hospital outpatient services by payment group (APC), 2024
| Service group | Services | Patients | Medicare pays per service | All hospitals |
|---|---|---|---|---|
| APC 8011 Comprehensive Observation Services | 72 | 63 | $1,874.64 | $2,090.36 |
| APC 5115 Level 5 Musculoskeletal Procedures | 36 | 34 | $9,688.84 | $10,771.69 |
| APC 5373 Level 3 Urology and Related Services | 28 | 23 | $1,398.14 | $1,516.28 |
| APC 5361 Level 1 Laparoscopy and Related Services | 22 | 22 | $3,439.47 | $4,357.80 |
| APC 5302 Level 2 Upper GI Procedures | 22 | 21 | $1,328.43 | $1,444.50 |
| APC 5375 Level 5 Urology and Related Services | 18 | 17 | $3,551.87 | $3,917.51 |
| APC 5114 Level 4 Musculoskeletal Procedures | 18 | 18 | $4,365.17 | $5,338.75 |
| APC 5374 Level 4 Urology and Related Services | 18 | 15 | $2,391.64 | $2,629.24 |
| APC 5072 Level 2 Excision/ Biopsy/ Incision and Drainage | 17 | 16 | $1,112.91 | $1,219.56 |
| APC 5376 Level 6 Urology and Related Services | 11 | 11 | $5,748.79 | $7,291.09 |
| APC 5113 Level 3 Musculoskeletal Procedures | 11 | 11 | $2,221.89 | $2,373.24 |
| APC 5191 Level 1 Endovascular Procedures | - | - | - | $2,207.96 |
Reported payments to this teaching hospital
Official US government data on Original Medicare hospital stays and outpatient services; groups with fewer than 11 cases are not published. Payments are those drug and device companies must report.
Tristar Southern Hills Medical Center is a for-profit short-term acute care hospital in Nashville, TN with 112 beds, part of HCA Healthcare and a 4-star overall rating.
Tristar Southern Hills Medical Center in Nashville, TN has 112 beds (fiscal year 2025 cost report); 136 beds are certified for Medicare. It discharged 5,005 inpatients that year, with 51.7% of its beds in use on average.
In fiscal year 2025 (ending 2025-05-31), Tristar Southern Hills Medical Center reported net patient revenue of $163.6M and operating expenses of $135.7M, a margin on patient care of 17.0%. After other income and expenses its net income was $29.0M (17.6% of revenue), so it made a profit that year.
Tristar Southern Hills Medical Center is part of HCA Healthcare (listed company, ticker HCA), a health system with 163 hospitals based in Nashville, TN. It is a for-profit hospital.
Tristar Southern Hills Medical Center has an overall rating of 4 out of 5 stars in the official hospital quality ratings. Patients rate it 3 out of 5 stars in the patient survey.
Yes, Tristar Southern Hills Medical Center provides emergency services.
205 Medicare clinicians list Tristar Southern Hills Medical Center as a hospital they work at, most often in Internal Medicine, Family Practice, Certified Registered Nurse Anesthetist (Crna).
In 2024, Tristar Southern Hills Medical Center had 379 Medicare inpatient stays in 14 diagnosis groups. The most common was DRG 871 (septicemia or severe sepsis without mv >96 hours with mcc) with 134 stays; Medicare paid $13,310.27 per stay on average, compared with $15,524.21 across all hospitals.
In 2025, companies reported $1,841 in payments to Tristar Southern Hills Medical Center as a teaching hospital ($1,841 general and - for research) from 3 companies.